TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards February 7, 1997
